The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Descending
Jan 2020
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
Clinical Drug Investigation
AUTHOR(S)
Aug 2019
Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
Neuropsychiatric Disease and Treatment
AUTHOR(S)
Aug 2019
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
CNS Spectrums
AUTHOR(S)
Jul 2019
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
Drug Design, Development and Therapy
AUTHOR(S)
Jul 2019
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period
CNS Spectrums
AUTHOR(S)
Jun 2019
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
Therapeutic Advances in Psychopharmacology
AUTHOR(S)
Jun 2019
Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder
Journal of the American Psychiatric Nurses Association
AUTHOR(S)
May 2019
Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study
Schizophrenia Research
AUTHOR(S)
Apr 2019
Effect of food on the pharmacokinetics of a combination of olanzapine and samidorphan
Clinical Pharmacology in Drug Development
AUTHOR(S)
Apr 2019
A phase-1 open-label study to evaluate the effects of rifampin on the pharmacokinetics of olanzapine and samidorphan administered in combination in healthy human subjects
Clinical Drug Investigation
AUTHOR(S)
